UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Main results already published
Unique ID issued by UMIN UMIN000007421
Receipt No. R000008700
Scientific Title Phase II study of TAS-102 in patients with advanced gastric cancer after progression on 1 or 2 prior systemic chemotherapy
Date of disclosure of the study information 2012/03/02
Last modified on 2017/01/05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Phase II study of TAS-102 in patients with advanced gastric cancer after progression on 1 or 2 prior systemic chemotherapy
Acronym TAS-102 Phase II GC
Scientific Title Phase II study of TAS-102 in patients with advanced gastric cancer after progression on 1 or 2 prior systemic chemotherapy
Scientific Title:Acronym TAS-102 Phase II GC
Region
Japan

Condition
Condition advanced gastric cancer
Classification by specialty
Gastroenterology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To evaluate the efficacy and safety of TAS-102 in patients with advanced gastric cancer after progression on 1 or 2 prior systemic chemotherapy.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2
Developmental phase Phase II

Assessment
Primary outcomes Disease control rate (DCR)
Key secondary outcomes Response rate (RR)
Progression free survival (PFS)
Overall survival (OS)
Adverse events
PK parameter

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 TAS-102 (35 mg/m2/dose BID) is administered orally on Day1-5 and Day8-12 in 28-day cycles.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1) Histologically proven gastric adenocarcinoma or gastro-esophageal junction adenocarcinoma.
2) Inoperable, recurrent or metastatic disease.
3) Tumor progression during prior chemotherapy or within 2 months after prior chemotherapy.
4) >= 20 years old.
5) ECOG performance status of <= 2.
6) Measurable disease without irradiation according to RECIST ver1.1.
7) Prior chemotherapies for advanced gastric cancer are as follows. (In case of progression during adjuvant/neoadjuvant therapy or <= 6 months after the last administration of adjuvant/neoadjuvant therapy, the adjuvant/neoadjuvant therapy will be considered one prior treatment.)
i. Include chemotherapy with 5-FU.
ii. Include chemotherapy with platinum derivative.
iii. Include chemotherapy with taxane or irinotecan.
iv. No. of prior chemotherapies <= 2.
8) Adequate organ function.
9) No blood transfusion within 14 days prior to enrollment.
10) AE related to prior chemotherapy, radiation therapy or surgery must be Grade <= 1 according to CTCAE. (except alopecia, peripheral sensory neuropathy, skin hyperpigmentation and dysgeusia)
11) Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to enrollment.
12) Adequate oral intake.
13) Written informed consent.
Key exclusion criteria 1) Administration of chemotherapy within 2 weeks prior to enrollment.
2) Major surgery or radiation therapy within 4 weeks prior to enrollment. Except bowel bypass surgery or enterostomy has passed over 2 weeks.
3) Investigational drugs were administrated within 4 weeks prior to enrollment.
4) Prior chemotherapy with TAS-102.
5) Known hypersensitivity to TAS-102 or excipients.
6) Patients with CNS metastases.
7) Malignant pleural effusion, ascites or cardiac effusion requiring invasive treatment. (such as ascites drainage)
8) Synchronous or asynchronous (within 3 years) other cancer except carcinoma in situ or intramucosal carcinoma.
9) Any severe and/or uncontrolled medical conditions.
10) Positive HBs antigen or HCV antibody. Known positive serology for HIV.
11) Chronic treatment with steroids or another immunosuppressive agent.
12) Not use adequate methods of contraception. (duplex barrier method or intrauterine device)
13) Patient is unwilling or unable to comply with the protocol.
14) Patient is judged by the investigator to be inappropriate for study participation for any reason.
Target sample size 28

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Toshihiko Doi
Organization National Cancer Center Hospital East
Division name Gastrointestinal Oncology Division
Zip code
Address 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan
TEL 04-7133-1111
Email tdoi@east.ncc.go.jp

Public contact
Name of contact person
1st name
Middle name
Last name Hideaki, BANDO, M.D.
Organization National Cancer Center Hospital East
Division name Gastrointestinal Oncology Division
Zip code
Address 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan
TEL 04-7133-1111
Homepage URL
Email hbando@east.ncc.go.jp

Sponsor
Institute National Cancer Center Hospital East
Institute
Department

Funding Source
Organization Health and Labor Sciences Research Grant
Organization
Division
Category of Funding Organization Japanese Governmental office
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor Taiho Pharmaceutical Co., Ltd.
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 独立行政法人国立がん研究センター東病院(千葉県)
静岡県立静岡がんセンター(静岡県)
愛知県がんセンター中央病院(愛知県)
独立行政法人国立病院機構四国がんセンター(愛媛県)
埼玉県立がんセンター(埼玉県)
公益財団法人がん研究会有明病院(東京都)

Other administrative information
Date of disclosure of the study information
2012 Year 03 Month 02 Day

Related information
URL releasing protocol
Publication of results Published

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Main results already published
Date of protocol fixation
2011 Year 12 Month 14 Day
Date of IRB
Anticipated trial start date
2012 Year 03 Month 01 Day
Last follow-up date
2014 Year 03 Month 01 Day
Date of closure to data entry
2014 Year 04 Month 30 Day
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2012 Year 03 Month 01 Day
Last modified on
2017 Year 01 Month 05 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008700

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.